SEC Filing Analysis: Oncolytics Biotech Inc. (ONCY)

Executive Summary

• Trading Significance: High
• Key Takeaway: Investment firm Anson Funds Management LP has reported beneficial ownership of 7,649,050 shares, representing a 7% stake in Oncolytics Biotech, a significant position for a small-cap company.
• Market Impact: This disclosure of a large institutional stake can attract market attention, potentially leading to increased trading volume and scrutiny of the company's strategy and performance.

Company Information

Field	Value
Company	ONCOLYTICS BIOTECH INC
Ticker Symbol	ONCY
CIK	0001129928
Industry	Pharmaceutical Preparations

Filer Information

Field	Value
Name	Anson Funds Management LP
CIK	0001491072
Title/Position	N/A (External Investor)
Relationship	Beneficial Owner of more than 5%

Transaction Details

Field	Value
Form Type	SCHEDULE 13G/A
Transaction Date	N/A (Statement as of 2025-09-30)
Transaction Code	N/A
Security Type	Common Stock underlying Warrants
Shares Involved	N/A
Price Per Share	N/A
Total Value	N/A
Shares Owned After	7,649,050
Ownership Type	Indirect

Financial Impact Assessment

Position Materiality

Metric	Value
Value of Holding (approx.)	$8,383,399
% of Market Cap	7.62%
Shares Held	7,649,050
% of Shares Outstanding	7.62%
Post-Transaction Ownership	7,649,050 shares (7.0% of class per filing)
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: For Oncolytics Biotech, a company with a market capitalization of $110 million, a single investor holding a stake valued at approximately $8.4 million is a major factor. This represents a significant concentration of ownership.
• Ownership Concentration: Anson Funds' position of 7.62% of the total shares outstanding makes it one of the largest shareholders. Such a large stake gives the fund considerable influence and indicates a strong conviction in the investment.
• Transaction Significance: The position is Highly Significant as the number of shares held (7,649,050) represents 7.62% of the shares outstanding, far exceeding the 0.5% threshold for high significance. The value of the stake also represents 7.62% of the company's market cap, well above the 1% threshold.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: A Schedule 13G filing indicates a passive investment intent (not seeking to influence or control the company). While the large stake is notable and could be perceived as a vote of confidence, the passive nature of the filing tempers immediate bullish interpretations. It primarily serves as a factual statement of significant ownership.

Volume & Sentiment

• Expected Volume Impact: A potential short-term increase in trading volume as the market digests the news of a large institutional stakeholder. The presence of a well-known fund can increase investor interest.
• Sentiment Indicator: Neutral to Bullish. The market often views the accumulation of a large stake by a professional investment firm as a positive sign, but the 'passive' nature of the 13G filing itself is neutral.

Investment Insights

Positive Market Indicators

• A professional investment fund has committed a significant amount of capital, suggesting a belief in the company's underlying value or future prospects.
• The large stake provides a degree of validation for the company's technology and market position within the small-cap biotech space.

Risk Factors

• High ownership concentration means that a future decision by Anson Funds to sell its stake could create significant downward pressure on the stock price.
• The ownership is held via warrants, which introduces complexity regarding potential future dilution upon exercise.

Key Takeaways

1. Significant Institutional Stake: Anson Funds holds a 7% beneficial ownership stake, making it a key institutional shareholder in Oncolytics Biotech.
2. High Materiality: The position represents over 7.6% of the company's market cap and shares outstanding, classifying it as a highly significant holding.
3. Passive Investment: The filing on a Schedule 13G indicates the stake was not acquired for the purpose of changing or influencing control of the company.

Additional Context

Transaction Notes

• This filing is a Schedule 13G/A (Amendment), indicating an update to a previously reported position. The event date triggering the filing was September 30, 2025.
• The beneficial ownership is held through shares of common stock underlying warrants, not direct common stock purchases on the open market.